Akèy › Kansè Poumon ki pa ti selil › Wisconsin › La Crosse
Etid klinik pou Kansè Poumon ki pa ti selil nan La Crosse, WI
10 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote La Crosse (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Gundersen Lutheran Medical Center, La Crosse
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Gundersen Lutheran Medical Center, La Crosse
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Gundersen Lutheran Medical Center, La Crosse
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Gundersen Lutheran Medical Center, La Crosse
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Gundersen Lutheran Medical Center, La Crosse
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Gundersen Lutheran Medical Center, La Crosse
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Gundersen Lutheran Medical Center, La Crosse
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Gundersen Lutheran Medical Center, La Crosse
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Gundersen Lutheran Medical Center, La Crosse
- Mayo Clinic Health System-Franciscan Healthcare, La Crosse
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Gundersen Health System, La Crosse
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan La Crosse
- Kansè poumon9 etid
- Kansè nan tete6 etid
- Leksemi mieloïd egi6 etid
- Myelom Miltip4 etid
- Limfom Difize Gwo Selil B3 etid
- Kansè larinks3 etid
- Kansè bouch3 etid
- Karsinòm selil skuamèz tèt ak kou3 etid
- Kansè Endomèt3 etid
- Kansè ovè3 etid
- Melanom3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.